Drug Trial Radar · NCT06220864
SNV1521 in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Feb 23, 2024
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- ParVation Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.
Conditions
- Advanced Solid Tumor
Interventions
SNV1521Drug
SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
DB-1310Drug
DB-1310 is given as an infusion. Dose and frequency are dependent upon treatment arm.
AbirateroneDrug
Abiraterone is taken orally. Dose and frequency are per approved prescribing instructions.
DarolutamideDrug
Darolutamide is taken orally. Dose and frequency are per approved prescribing instructions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of SNV1521Time frame: From first dose through last dose (up to 13 months)
- Tolerability of SNV1521Time frame: DLTs: From first dose through completion of first cycle (28 days)
Locations
25 sites in 7 countries. Site status is shown where the registry gives one.
Smilow Cancer Hospital at Yale New Haven
New Haven, Connecticut · Recruiting
Thomas Jefferson University
Philadelphia, Pennsylvania · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Recruiting
The University of Texas M.D. Anderson Cancer Center
Houston, Texas · Recruiting
START Center for Cancer Care
West Valley City, Utah · Recruiting
Scientia Clinical Research
Randwick, New South Wales, Australia · Recruiting
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia · Recruiting
Monash Health
Clayton, Victoria, Australia · Recruiting
The Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Linear Clinical Research
Crawley, Western Australia, Australia · Recruiting
The Institut Jules Bordet
Brussels, Belgium · Recruiting
University Center for Clinical Research Antwerp (UNICCRA)
Edegem, Belgium · Recruiting
AZ Maria Middelares
Ghent, Belgium · Recruiting
AZ Groeninge
Kortrijk, Belgium · Recruiting
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, Canada · Recruiting
Princess Margaret Hospital
Toronto, Ontario, Canada · Recruiting
Institut Bergonie
Bordeaux, France · Recruiting
UNICANCER - Centre Leon-Berard (CLB)
Lyon, France · Recruiting
Gustave Roussy
Villejuif, France · Recruiting
Istituto Clinico Humanitas
Milan, Italy · Recruiting
Istituto Europeo di Oncologia (IEO) (European Institute of Oncology)
Milan, Italy · Recruiting
NEXT Oncology - Barcelona
Barcelona, Spain · Recruiting
Vall d'Hebron University Hospital
Barcelona, Spain · Recruiting
The START Center for Cancer Care - Madrid - CIOCC - Hospital Universitario Madrid Sanchinarro
Madrid, Spain · Recruiting
NEXT Oncology - Hospital Quironsalud Madrid
Madrid, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.